Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-18T18:24:22.465Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum-soluble suppression of tumourigenicity-2 as a biomarker in children with congestive heart failure

Published online by Cambridge University Press:  13 March 2023

Eslam Amer ,
Doaa El Amrousy Open the ORCID record for Doaa El Amrousy [Opens in a new window] ,
Sahar Hazaa  and
Amr Zoair
Eslam Amer
Affiliation:
Pediatric Department, Faculty of Medicine, Tanta University, Egypt
Doaa El Amrousy*
Affiliation:
Pediatric Department, Faculty of Medicine, Tanta University, Egypt
Sahar Hazaa
Affiliation:
Clinical Pathology Department, Faculty of Medicine, Tanta University, Egypt
Amr Zoair
Affiliation:
Pediatric Department, Faculty of Medicine, Tanta University, Egypt
*
Author for correspondence: Doaa El Amrousy, MD Pediatrics, Professor of Pediatrics, Tanta University Hospital, Tanta, Egypt. Tel: +201289022229; Fax: +20403280477. E-mail: doaamoha@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

We aimed to evaluate serum soluble suppression of tumorigenicity-2 in children with congestive heart failure, to assess the diagnostic and prognostic values of soluble suppression of tumorigenicity-2 in these patients, and to correlate its levels with various clinical and echocardiographic data.

Methods:

We included 60 children with congestive heart failure as the patient group. Sixty healthy children of matched age and sex served as the control group. Patients were evaluated clinically and by echocardiography. Serum level of suppression of tumorigenicity-2 was measured for patients at admission. All patients were followed up for death or readmission for a period of one year.

Results:

Soluble suppression of tumorigenicity-2 was significantly higher in children with congestive heart failure as compared to the control group. Soluble suppression of tumorigenicity-2 was significantly increased in patients with higher severity of congestive heart failure. There was a significant increase in soluble suppression of tumorigenicity-2 in patients with bad prognosis compared to those with good prognosis. There was a significant positive correlation between soluble suppression of tumorigenicity-2 and respiratory rate, heart rate, and clinical stage of congenital heart failure, while there was a significant negative correlation between soluble suppression of tumorigenicity-2 and left ventricular systolic and diastolic function. The best cut-off of soluble suppression of tumorigenicity-2 to diagnose congestive heart failure was > 3.6 with 87% sensitivity and 79% specificity. The cut-off point of soluble suppression of tumorigenicity-2 to diagnose congestive heart failure in children was ≥ 31.56 ng/ml, with 95% sensitivity and 91.37% specificity. Moreover, the cut-off point of soluble suppression of tumorigenicity-2 to predict bad prognosis in children with congestive heart failure was ≥ 255.5 ng/ml, with 92% sensitivity and 89.0% specificity.

Conclusion:

Soluble suppression of tumorigenicity-2 is a good diagnostic and predictive biomarker in children with congestive heart failure.

Keywords

Suppression of tumorigenicity-2diagnosticpredictivepaediatric heart failure
Type
Original Article
Information
Cardiology in the Young , Volume 33 , Issue 12 , December 2023 , pp. 2481 - 2486
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cleland, JG, Khand, A, Clark, A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001; 22: 623–626.CrossRefGoogle Scholar
El Amrousy, D, Hodeib, H, Suliman, G, Hablas, N, Salama, ER, Esam, A. Diagnostic and prognostic value of plasma levels of cardiac myosin binding protein-C as a novel biomarker in heart failure. Pediatr Cardiol 2017; 38: 418–424.CrossRefGoogle ScholarPubMed
El Amrousy, D, Abdelhai, D, Nassar, M. Predictive value of plasma copeptin level in children with acute heart failure. Pediatr Cardiol 2022; 43: 1737–1742.CrossRefGoogle ScholarPubMed
Sharim, J, Daniels, LB. Soluble ST2 and soluble markers of fibrosis: emerging roles for prognosis and guiding therapy. Curr Cardiol Rep 2020; 22: 41.CrossRefGoogle ScholarPubMed
Ky, B, French, B, McCloskey, K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180–187.CrossRefGoogle ScholarPubMed
Kakkar, R, Lee, RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev Drug Discov 2008; 7: 827–840.CrossRefGoogle ScholarPubMed
Aimo, A, Vergaro, G, Ripoli, A, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail 2017; 5: 280–286.CrossRefGoogle ScholarPubMed
Aimo, A, Januzzi, JL Jr, Bayes-Genis, A, et al. Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week. J Am Coll Cardiol 2019; 74: 2193–2203.CrossRefGoogle ScholarPubMed
Boisot, S, Beede, J, Isakson, S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008; 14: 732–738.CrossRefGoogle ScholarPubMed
Gaggin, HK, Szymonifka, J, Bhardwaj, A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2014; 2: 65–72.CrossRefGoogle ScholarPubMed
Tang, WH, Wu, Y, Grodin, JL, et al. Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. JACC Heart Fail 2016; 4: 68–77.CrossRefGoogle ScholarPubMed
Yancy, CW, Jessup, M, Bozkurt, B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137–e161.CrossRefGoogle Scholar
Aimo, A, Maisel, AS, Castiglione, V, Emdin, M. sST2 for outcome prediction in acute heart failure: which is the best cutoff? J Am Coll Cardiol 2019; 74: 478–479.CrossRefGoogle ScholarPubMed
Parikh, RH, Seliger, SL, Christenson, R, Gottdiener, JS, Psaty, BM, deFilippi, CR. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. J Am Heart Assoc 2016; 5: e003188.CrossRefGoogle Scholar
Aimo, A, Vergaro, G, Passino, C, et al. Prognostic value of soluble suppression of Tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail 2017; 5: 280–286.CrossRefGoogle ScholarPubMed
Mizuno, R, Fujimoto, S, Saito, Y, Nakamura, S. Non –invasive quantitation of myocardial fibrosis using integrated backscatter analysis in dilated cardiomyopathy. Cardiology 2007; 108: 11–17.CrossRefGoogle ScholarPubMed
Wu, AH, Wians, F, Jaffe, A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013; 165: 9959–999.CrossRefGoogle ScholarPubMed
Masarone, D, Valente, F, Rubino, M, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol 2017; 58: 303–312.CrossRefGoogle ScholarPubMed
Abdel Raheem, M, Sedik, WF. Prognostic value of soluble ST2 (sST2) serum levels in infants and children with heart failure complicating congenital heart disease. Int J Pediatr 2019; 7: 9471–9480.Google Scholar
Larsen, KM, Minaya, MK, Vaish, V, Peña, MMO. The role of IL-33/ST2 pathway in tumorigenesis. Int J Mol Sci 2018; 19: 2676.CrossRefGoogle ScholarPubMed
Pascual-Figal, DA, Januzzi, JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol 2015; 115: 3B–7B.CrossRefGoogle ScholarPubMed
Iannazzo, F, Pellicano, C, Colalillo, A, et al. Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement. Clin Exp Med 2022; 10: 21203.Google Scholar
Wang, Z, Pan, X, Xu, H, et al. Serum soluble ST2 is a valuable prognostic biomarker in patients with acute heart failure. Front Cardiovasc Med 2022; 10: 812654.CrossRefGoogle Scholar
Miftode, RS, Constantinescu, D, Cianga, CM, et al. A novel paradigm based on ST2 and its contribution towards a multimarker approach in the diagnosis and prognosis of heart failure: a prospective study during the pandemic storm. Life 2021; 11: 1080.CrossRefGoogle ScholarPubMed
Xia, J, Qu, Y, Yin, C, Xu, D. Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction. Cardiol J 2017; 24: 188–194.CrossRefGoogle Scholar
Sanada, S, Hakuno, D, Higgins, LJ, Schreiter, ER, McKenzie, ANJ, Lee, RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig 2007; 117: 1538–1549.CrossRefGoogle ScholarPubMed
Ponikowska, B, Iwanek, G, Zdanowicz, A, et al. Biomarkers of myocardial injury and remodeling in heart failure. J Personal Med 2022; 12: 799.CrossRefGoogle ScholarPubMed
Dalal, JJ, Digrajkar, A, Das, B, Bansal, M, Toomu, A, Maisel, AS. ST2 elevation in heart failure, predictive of a high early mortality. Indian Heart J 2018; 70: 822–827.CrossRefGoogle ScholarPubMed
Biasucci, LM, Maino, A, Grimaldi, MC, Cappannoli, L, Aspromonte, N. Novel biomarkers in heart failure: new insight in pathophysiology and clinical perspective. J Clin Med 2021; 10: 2771.CrossRefGoogle ScholarPubMed
Kanagala, P, Arnold, JR, Singh, A. Characterizing heart failure with preserved and reduced ejection fraction: an imaging and plasma biomarker approach. PLoS One 2020; 15: e0232280.CrossRefGoogle ScholarPubMed
Zannad, F, Gattis, SW, Rossignol, P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33: 2782–2795.CrossRefGoogle ScholarPubMed